Trial reportThe Journal of clinical endocrinology and metabolism2005
Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study.
Trial report in The Journal of clinical endocrinology and metabolism, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06064669 (Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus), which is not on this map. Cited by 76 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus: a Multicenter Double-blind Placebo Controlled Randomized Trial
Who cites it
76 citing papers in PubMed, 4 syntheses or guidelines pooled it, 308 citations in OpenAlex.
- Serum vitamin D levels in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Association of vitamin D receptor gene variants with polycystic ovary syndrome: a meta-analysis.BMC medical genetics · 2019Pooled it
- Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.The Journal of clinical endocrinology and metabolism · 2013 · on this mapGuideline
- Oligomenorrhoea in exercising women: a polycystic ovarian syndrome phenotype or distinct entity?Sports medicine (Auckland, N.Z.) · 2009Pooled it
- Trial
- Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.The Journal of clinical endocrinology and metabolism · 2021Trial
- The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients.Scientific reports · 2019Trial
- Association of Androgen Excess with Glucose Intolerance in Women with Polycystic Ovary Syndrome.BioMed research international · 2018Trial
- Mindfulness-based stress reduction for overweight/obese women with and without polycystic ovary syndrome: design and methods of a pilot randomized controlled trial.Contemporary clinical trials · 2015Trial
- Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study.Clinics (Sao Paulo, Brazil) · 2012Trial
- Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome.Fertility and sterility · 2009Trial
- Gut microbiota, lipid metabolism, and PCOS: A Mendelian randomization and mediation analysis.Medicine · 2026Article
- Rare Variation in LMNA Underlies Polycystic Ovary Syndrome Pathogenesis in 2 Independent Cohorts.The Journal of clinical endocrinology and metabolism · 2025Article
- The Role of Diet, Glycaemic Index and Glucose Control in Polycystic Ovary Syndrome (PCOS) Management and Mechanisms of Progression.Current nutrition reports · 2025Review
- Influence of Phenotypes on the Metabolic Syndrome of Women with Polycystic Ovary Syndrome over a Six-Year Follow-Up in Brazil.Biomedicines · 2023Article
- Common clinical laboratory features among women with polycystic ovary syndrome and metabolic syndrome.Journal of medicine and life · 2023Article
- The Potential of SGLT-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: The Current Status and Future Perspectives.Biomedicines · 2023Review
- The effect of hyperandrogenism and obesity on mindfulness and metacognition in adolescents with polycystic ovary syndrome.Archives of women's mental health · 2022Article
- A meta-analysis of the association of ApaI, BsmI, FokI, and TaqI polymorphisms in the vitamin D receptor gene with the risk of polycystic ovary syndrome in the Eastern Mediterranean Regional Office population.International journal of reproductive biomedicine · 2022Review
- Higher risk of type 2 diabetes in young women with polycystic ovary syndrome: A 10-year retrospective cohort study.World journal of diabetes · 2022Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
We performed this study to access the changes in glucose tolerance over time in a group of women with polycystic ovary syndrome (PCOS) (n = 71) and control women (n = 23) with regular menstrual cycles and baseline normal glucose tolerance. Mean follow-up was between 2 and 3 yr for both groups (PCOS 2.5 +/- 1.7 yr; controls 2.9 +/- 2.1 yr). Based on World Health Organization glucose tolerance categories, there was no significant difference in the prevalence of glucose intolerance at follow-up in the PCOS group. In the PCOS group, 25 (37%) had impaired glucose tolerance (IGT) and seven (10%) had type 2 diabetes mellitus at baseline, compared with 30 (45%) and 10 (15%), respectively, at follow-up. There were also no differences within groups (PCOS or control) or between groups (PCOS vs. control) in the oral glucose tolerance test-derived measure of insulin sensitivity, but in the women with PCOS who converted to either IGT or type 2 diabetes mellitus, there was a significant decrease (P < 0.0001). At the follow-up visit, the mean glycohemoglobin level was 6.1 +/- 0.9% in women with PCOS vs. 5.3 +/- 0.7% in the control women (P < 0.001). Women with PCOS and baseline IGT had a low conversion risk of 6% to type 2 diabetes over approximately 3 yr, or 2% per year. The effect of PCOS, given normal glucose tolerance (NGT) at baseline, is more pronounced with 16% conversion to IGT per year. Our study supports that women with PCOS (especially with NGT) should be periodically rescreened for diabetes due to worsening glucose intolerance over time, but this interval may be over several years and not annually.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.